Thelansis

Neuroblastoma (NB) Market Access and Reimbursement Insights Thelansis’s “Neuroblastoma (NB) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Neuroblastoma (NB) Overview Neuroblastoma is a malignant tumor of neural crest-derived sympathetic cells, primarily affecting children under 5. It may occur sporadically or in familial cases linked to ALK or PHOX2B mutations (autosomal dominant). Prognosis is strongly influenced by MYCN amplification and chromosomal aberrations. BARD1 and LIN28B polymorphisms are associated with susceptibility. Diagnosis relies on urinary catecholamine metabolites (HVA, VMA), CT/MRI imaging, and ...

Neuroblastoma (NB) Emerging Therapy and TPP Insights Thelansis’s “Neuroblastoma (NB) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Neuroblastoma (NB) Overview Neuroblastoma is a malignant tumor of neural crest-derived sympathetic cells, primarily affecting children under 5. It may occur sporadically or in familial cases linked to ALK or PHOX2B mutations (autosomal dominant). Prognosis is strongly influenced by MYCN amplification and chromosomal aberrations. BARD1 and LIN28B polymorphisms are associated with susceptibility. Diagnosis relies on urinary catecholamine metabolites (HVA, VMA), CT/MRI imaging, and MIBG scintigraphy for metastasis. Bone marrow biopsy is used for staging. Differential diagnoses include Wilms tum...

Neuroblastoma (NB) Market Access and Reimbursement Insights Thelansis’s “Neuroblastoma (NB) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve market access Pricin...

Neuroblastoma (NB) Emerging Therapy and TPP Insights Thelansis’s “Neuroblastoma (NB) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity sizing for key unmet needs Target Product Profiles Attribu...

Neuroblastoma (NB) Market Outlook Thelansis’s “Neuroblastoma (NB) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neuroblastoma (NB) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What in...

Neuroblastoma (NB) Market Outlook Thelansis’s “Neuroblastoma (NB) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neuroblastoma (NB)     treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Neuroblastoma (NB) Overview Neuroblastoma, a malignant tumor originating from neural crest cells responsible for the sympathetic nervous system, predominantly affects children. Its occurrence may be sporadic or inherited in the germline, with familial cases often linked to mutations in ALK or PHOX2B genes. Some familial cases exhibit autosomal dominant inheritance. Additionally, common transforming mutations involve polymorphisms in genes li...

 Neuroblastoma, a malignant tumor originating from neural crest cells responsible for the sympathetic nervous system, predominantly affects children. Its occurrence may be sporadic or inherited in the germline, with familial cases often linked to mutations in ALK or PHOX2B genes. Some familial cases exhibit autosomal dominant inheritance. Additionally, common transforming mutations involve polymorphisms in genes like BARD1, LIN28B, or FLJ22536. Genetic anomalies, including MYCN amplification and chromosomal abnormalities, significantly impact prognosis. Diagnosis relies on elevated urinary catecholamine metabolites and imaging techniques like ultrasound, brain scan, or MRI. MIBG scintigraphy and medullary analysis aid in metastasis detection. Differential diagnosis includes nephroblastoma, while bone pain and limp may be mistaken for hip synovitis, and peri-orbital hematomas are misinterpreted as maltreatment signs. Treatment modalities encompass surgery, chemotherapy, radiotherapy...

 Neuroblastoma (NB) is the most common extracranial solid tumor in childhood, accounting for more than 7% of malignancies in children younger than 15 years of age and 15% of all pediatric oncology deaths. It is a heterogeneous malignancy with a broad spectrum of clinical behavior. Extensive clinical and basic research over the last four decades has shed light on the biology and treatment of neuroblastoma, but despite remarkable progress, important challenges remain. The current staging system uses clinical characteristics and imaging defined risk factors to stage the disease as L1, L2, M, or MS. Locoregional tumors are designated as either L1 or L2 based on the presence or absence of anatomic characteristics that would make complete surgical excision unsafe or impracticable at the time of diagnosis. ·        In the USA, the incidence of Neuroblastoma (NB) per year is 10.5 per million children less than 15 years of age. Neuroblastoma accounts for 8% t...

  Neuroblastoma is the most common extracranial solid tumor in childhood, accounting for more than 7% of malignancies in children younger than 15 years of age and 15% of all pediatric oncology deaths. It is a heterogeneous malignancy with a broad spectrum of clinical behavior. Extensive clinical and basic research over the last four decades has shed light on the biology and treatment of neuroblastoma, but despite remarkable progress, significant challenges remain. The current staging system uses clinical characteristics and imaging defined risk factors to stage the disease as L1, L2, M, or MS. Locoregional tumors are designated as either L1 or L2 based on the presence or absence of anatomic characteristics that would make complete surgical excision unsafe or impracticable at the time of diagnosis.   In the USA, neuroblastoma per year is 10.5 per million children less than 15 years of age. Neuroblastoma accounts for 8% to 10% of all childhood cancers and approximately 15% o...